证券记录 · 已归档季度
RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
13被追踪持有人
-3Δ持有人
61.13M持有股份
$1.91B报告持仓市值
+0新建仓位
−3清仓
动量输入（同类管理人）：
持有人广度 -18.8% ·
股份流向 -20.9% ·
净新建仓位 -20.0%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 0 | 306.62M | $17.19B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 13.40M | -5.2% | $417.21M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 13.40M | -5.2% | $417.21M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 13.40M | -5.2% | $417.21M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 13.40M | -5.2% | $417.21M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 10.56M | -13.5% | $328.86M | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (被动) | 9.52M | -2.5% | $296.24M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (被动) | 8.00M | +9.4% | $253.46M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 8.00M | +9.4% | $253.46M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 6.25M | -63.2% | $194.56M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 10 | Norges Bank ✦ (被动) | 4.89M | +0.3% | $152.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 2.61M | +37.0% | $80.38M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 2.07M | -28.7% | $64.31M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 2.07M | -28.7% | $64.31M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 1.61M | -33.4% | $50.21M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 20 | Arrowstreet Capital ✦ | 1.36M | +103.1% | $42.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 309.17K | -87.2% | $9.62M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 275.84K | -76.2% | $8.59M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | T. Rowe Price ✦ | 269.46K | +9.3% | $8.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Point72 Asset Management | $6.35M | 曾为 0.0% |
| Bridgewater Associates | $1.26M | 曾为 0.0% |
| Wellington Management | $472,931 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 583 持有人, 354.58M 股份, $16.55B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 18
Hite Christopher
Officer · 100.00K 股 · $6.00M
Aug 13
Coyne Terrance P.
Officer · 9.23K 股 · $540,752
Aug 13
Coyne Terrance P.
Officer · 1.77K 股 · $104,799
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 17
SC 13D/A — Legorreta Pablo G.
18.7% 占股份类别 · 查看 SEC 原始申报文件 ↗
Jun 16
SC 13D/A — Severgnini Achille G.
4.8% 占股份类别 · 查看 SEC 原始申报文件 ↗
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据